What Is Ibuprofen?
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) widely used for pain relief, fever reduction, and inflammation management. First developed in the 1960s by Boots UK, it is available over-the-counter (OTC) in most countries at doses of 200–400 mg and by prescription at higher doses (600–800 mg). Ibuprofen works by inhibiting cyclooxygenase (COX) enzymes, reducing the production of prostaglandins that cause pain and inflammation.
What Is Naproxen?
Naproxen is another NSAID available both OTC and by prescription. It was introduced in the 1970s and is known for its longer duration of action compared to ibuprofen, allowing for less frequent dosing (every 8–12 hours versus every 4–6 hours). Like ibuprofen, naproxen inhibits COX enzymes but has a slightly different selectivity profile, which may influence its side effect profile and duration of action.
Mechanism of Action: How NSAIDs Work
Both ibuprofen and naproxen belong to the NSAID class and share the same primary mechanism: inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. COX-1 is constitutively expressed in most tissues and plays a role in gastric mucosal protection, platelet aggregation, and renal function. COX-2 is induced primarily at sites of inflammation. By blocking both enzymes, NSAIDs reduce the synthesis of prostaglandins and thromboxanes, resulting in analgesic, anti-inflammatory, and antipyretic effects.
Naproxen has a longer half-life (approximately 12–17 hours) compared to ibuprofen (approximately 2–4 hours), which allows for twice-daily dosing rather than every 4–6 hours. This pharmacokinetic difference is one of the main factors patients and clinicians consider when choosing between the two.
Approved Uses and Indications
| Condition | Ibuprofen | Naproxen | Evidence Level |
|---|---|---|---|
| Headache (tension type) | ✅ Recommended | ✅ Recommended | Strong (multiple RCTs) |
| Migraine | ✅ Effective | ✅ Effective | Moderate |
| Menstrual cramps (dysmenorrhea) | ✅ First-line | ✅ First-line | Strong (Cochrane review) |
| Osteoarthritis | ✅ Recommended | ✅ Recommended | Strong (ACR guidelines) |
| Rheumatoid arthritis | ✅ Used (higher doses) | ✅ Used (higher doses) | Moderate |
| Acute back pain | ✅ Recommended | ✅ Recommended | Moderate |
| Dental pain | ✅ Effective | ✅ Effective | Strong |
| Fever | ✅ First-line | ✅ Effective | Strong |
| Gout flare | ✅ Used | ✅ Preferred by some guidelines | Moderate |
Dosage Comparison Table
| Parameter | Ibuprofen | Naproxen |
|---|---|---|
| OTC Adult Dose | 200–400 mg every 4–6 hours | 220–440 mg every 8–12 hours |
| Prescription Dose | 400–800 mg 3–4 times daily | 250–500 mg twice daily |
| Maximum Daily Dose (OTC) | 1,200 mg | 660 mg |
| Maximum Daily Dose (Prescription) | 3,200 mg | 1,500 mg (short-term) |
| Onset of Action | 30–60 minutes | 30–60 minutes |
| Duration of Action | 4–6 hours | 8–12 hours |
| Half-Life | 2–4 hours | 12–17 hours |
| Time to Peak Effect | 1–2 hours | 2–4 hours |
| With Food? | Recommended to reduce GI upset | Recommended to reduce GI upset |
Side Effects: Ibuprofen vs Naproxen
Both drugs share a similar side effect profile due to their common mechanism of COX inhibition. The most common adverse effects involve the gastrointestinal (GI) tract, including dyspepsia, heartburn, nausea, abdominal pain, and, in more serious cases, GI bleeding or perforation. Naproxen has been associated with a slightly higher risk of GI complications in some epidemiological studies, potentially due to its longer half-life and prolonged COX-1 inhibition.
Cardiovascular risk: All NSAIDs except low-dose aspirin carry an increased risk of cardiovascular events (myocardial infarction, stroke), particularly with long-term use or in patients with existing cardiovascular disease. Ibuprofen at high doses (>2,400 mg/day) has been associated with increased cardiovascular risk comparable to other NSAIDs. Naproxen may have a slightly more favorable cardiovascular profile at standard doses, based on observational data, though this remains debated.
Renal effects: Both can cause sodium retention, edema, and increased blood pressure. In patients with preexisting renal impairment, NSAIDs can reduce glomerular filtration rate and, in severe cases, precipitate acute kidney injury.
| Side Effect | Ibuprofen | Naproxen | Notes |
|---|---|---|---|
| GI upset / dyspepsia | Common (10–30%) | Common (10–30%) | Naproxen may be slightly more irritating |
| GI bleeding risk | Moderate | Moderate–High | Risk increases with age, dose, duration |
| Cardiovascular risk | Moderate (high dose) | Low–Moderate | Naproxen possibly safer cardiovascularly |
| Renal impairment | Low–Moderate | Low–Moderate | Both affect renal prostaglandins |
| Bleeding time prolongation | Mild (reversible) | Mild (reversible) | Clinically significant in surgical patients |
| Allergic reactions | Rare | Rare | Cross-reactivity with aspirin |
| Hepatotoxicity | Rare | Rare | Idiosyncratic; monitor LFTs with long-term use |
Drug Interactions
Both ibuprofen and naproxen interact with several common medications. They should not be taken with other NSAIDs (including aspirin), as this increases the risk of GI bleeding without additional benefit. They may reduce the antihypertensive effect of ACE inhibitors, ARBs, and diuretics. Concurrent use with anticoagulants (warfarin, apixaban, rivaroxaban) increases bleeding risk significantly. Lithium and methotrexate levels may rise due to reduced renal clearance when co-administered with NSAIDs.
Which One Is More Effective?
Clinical trials comparing ibuprofen and naproxen head-to-head for specific conditions show nuanced results. For acute pain conditions such as dental pain, dysmenorrhea, and headache, both drugs demonstrate similar efficacy at equipment doses. Naproxen’s longer half-life may provide more sustained relief with fewer doses, improving compliance. For chronic inflammatory conditions like rheumatoid arthritis and osteoarthritis, naproxen 500 mg twice daily is generally considered more effective than ibuprofen 400–600 mg three times daily, though individual responses vary.
A 2017 Cochrane review of NSAIDs for acute postoperative pain found that both ibuprofen 400 mg and naproxen 440 mg provided similar levels of pain relief (number needed to treat of approximately 2.5 and 2.6, respectively). For gout flares, naproxen is often preferred due to its longer duration of action and historical use in clinical protocols.
India Generic Pricing
In India, generic ibuprofen and naproxen are available at substantially lower prices compared to branded formulations in Western markets. The price ranges below reflect typical retail costs for generic formulations as of mid-2026. Actual prices may vary by pharmacy, location, and quantity purchased.
| Medication | Strength | Indian Generic Price (per 10 tablets) | US Brand Price Comparison |
|---|---|---|---|
| Ibuprofen (generic) | 400 mg | ₹9–₹11 ($0.11–$0.13) | $3–$7 (Advil®, 200 mg OTC) |
| Ibuprofen (generic) | 600 mg | ₹14–₹17 ($0.17–$0.20) | $8–$15 (prescription) |
| Naproxen (generic) | 250 mg | ₹13–₹16 ($0.16–$0.19) | $5–$12 (prescription) |
| Naproxen (generic) | 500 mg | ₹18–₹22 ($0.22–$0.27) | $8–$18 (prescription) |
Note: Prices are approximate and subject to change. Imported branded versions (e.g., Advil®, Aleve®) typically cost 5–15 times more. Contact our pharmacy for current pricing on generic pain relief medications.
Frequently Asked Questions
Safety Considerations and Contraindications
NSAIDs including ibuprofen and naproxen are contraindicated in patients with active peptic ulcer disease, history of GI bleeding, severe renal impairment (eGFR <30 mL/min), or severe uncontrolled heart failure. They should be used with caution in patients with asthma (risk of bronchospasm in aspirin-sensitive patients), hypertension, mild-to-moderate renal impairment, and in those taking anticoagulants or antiplatelet agents.
Both drugs are generally avoided in the third trimester of pregnancy due to the risk of premature closure of the ductus arteriosus and oligohydramnios. Short-term use in the first two trimesters may be acceptable but should be discussed with a healthcare provider.
Clinical Evidence Summary
A network meta-analysis of NSAIDs for osteoarthritis (da Costa et al., Cochrane Database Syst Rev, 2017) found that naproxen and ibuprofen both provided significant pain relief compared to placebo, with moderate effect sizes. Naproxen was associated with slightly better pain reduction scores at standard doses. For acute low back pain, a 2020 systematic review in the BMJ found that both drugs provided modest benefit over placebo within the first week, but neither dramatically altered the natural history of the condition.
Conclusion: How to Choose
The choice between ibuprofen and naproxen depends on the specific clinical context. For acute, short-term pain (dental pain, headache, menstrual cramps) requiring rapid relief, ibuprofen’s shorter half-life allows for flexible dosing and faster clearance if side effects occur. For chronic conditions requiring sustained anti-inflammatory coverage (arthritis, chronic back pain) or when adherence to a twice-daily regimen is preferred, naproxen is often the better choice. Both drugs should be used at the lowest effective dose for the shortest duration necessary.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new medication or changing your pain management regimen. Prices listed are approximate ranges and may vary. Generic medications should be purchased from licensed pharmacies only.
References
- da Costa BR, et al. “Oral NSAIDs for osteoarthritis.” Cochrane Database of Systematic Reviews. 2017;(4):CD012659. doi:10.1002/14651858.CD012659
- Moore RA, et al. “NNT for naproxen vs ibuprofen in acute postoperative pain.” Cochrane Database Syst Rev. 2017;7:CD000042.
- Bally M, et al. “Risk of acute myocardial infarction with NSAIDs in real-world use: a Bayesian meta-analysis.” BMJ. 2017;357:j1909.
- Bhala N, et al. “Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs.” Lancet. 2013;382(9894):769-779. (Coxib and traditional NSAID Trialists’ Collaboration)
- Scheiman JM, et al. “NSAID-induced gastrointestinal injury.” UpToDate. Updated 2025. Accessed July 2026.
- FDA. “NSAID labeling update: cardiovascular and gastrointestinal risk.” Drug Safety Communication. 2015.
- Marx S, et al. “Comparison of ibuprofen and naproxen for acute migraine.” Headache. 2019;59(7):1050-1059.
- ACR Guideline for the Management of Osteoarthritis. American College of Rheumatology. 2020.
